Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pro-Pola Regimen in Elderly Newly Diagnosed DLBCL
NCT07072208Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Nov 2024
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib, polatuzumab vedotin, pomalidomide, rituximab in diffuse large B-cell lymphoma (DLBCL), sponsored by First Affiliated Hospital of Soochow University. Started Nov 2024; status: recruiting.
02
Drugs
orelabrutinibpolatuzumab vedotinpomalidomiderituximab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07072208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07072208.